Biomerica's inFoods® IBS Test receives $300 Medicare payment under CLFS, effective Jan 1, 2026.

Biomerica, Inc., based in Irvine, California, revealed on December 23, 2025, that the Centers for Medicare & Medicaid Services (CMS) has set the national Medicare payment rate at $300 for its inFoods® IBS test under the Clinical Laboratory Fee Schedule (CLFS). This rate will be applicable to claims for the InFoods IBS test approved and paid for by Medicare with service dates starting from January 1, 2026. Biomerica, Inc. is a leading provider of cutting-edge diagnostic solutions globally and is listed on Nasdaq under the symbol BMRA.